ライフサイエンスコーパス: discontinue

1 Additionally, oral steroids were discontinued.

2 as initiated and background medications were discontinued.

3 nt and memory deficits long after its use is discontinued.

4 ation occurring only after the anesthetic is discontinued.

5 ar after components of the intervention were discontinued.

6 ar after components of the intervention were discontinued.

7 rapy and chemotherapy, bacterial therapy was discontinued.

8 ing enzyme inhibitors and statins, should be discontinued.

9 ronal integration occurred only after it was discontinued.

10 -sensing machinery when shRNA expression was discontinued.

11 mpared with mice in which alphaIFN-gamma was discontinued.

12 A total of 199 trials (30.2%) were discontinued.

13 After 6 months, peer comparisons were discontinued.

14 mptoms cleared completely after the drug was discontinued.

15 e groups in which neurohumoral blockers were discontinued.

16 me to tumor recurrence after chemotherapy is discontinued.

17 atients receiving concomitant ITP medication discontinued 1 or more medication.

18 5 allocated to the 60 mg group and 92 to the discontinued 100 mg group.

19 Overall, 5 discontinued (2 due to sleep-related adverse events, 4.6

20 nsultation to guide the decision to start or discontinue a treatment.

21 95% CI, .101-.455) compared to patients who discontinued ACEi/ARB.

22 Conclusion: Discontinuing acetylcysteine based on laboratory testing

23 to use pegasparaginase or may unnecessarily discontinue administering it because of certain adverse

24 Reasons for the decision to discontinue after having decided to initiate PrEP were e

25 t transfer data; and prevalence surveys were discontinued after 2 consecutive negative surveys.

26 for all three patients, and antibiotics were discontinued after 2 days in the second and third patien

27 historically high transmission where IRS was discontinued after a 4-year period followed by universal

28 e >=2 for men and >=3 for women, 23% had OAC discontinued after ablation.

29 Chemotherapy could be discontinued after six cycles if a maximum response was

30 re less likely than matched RYGB patients to discontinue all diabetes medications (hazard ratio 0.80,

31 s later, against medical advice, the patient discontinued all immunosuppression.

32 rary dose modifications, and 17% permanently discontinued all three study drugs due to TRAEs.

33 After LT, 21 (42%) patients were able to discontinue and remained off PA-targeted therapy.

34 After ART was discontinued and as the virus began to spread, an appare

35 enous anesthetic/anxiolytic medications were discontinued and cognitive testing was completed.

36 The patient's anti-IL-17 medication was discontinued and endoscopic remission was induced with t

37 red to the first patient, antimetabolite was discontinued and only hydroxychloroquine was started.

38 criterion, the trial product was permanently discontinued and patients were not withdrawn from trial

39 s ratio, 0.15; 95% CI, 0.07-0.34) and orders discontinued and rewritten at the time of transfer from

40 ever, previous clinical candidates have been discontinued and the link between FLAP inhibition and ou

41 Pancrelipase was discontinued and the patient was prescribed ivacaftor 15

42 fore, the immunosuppressive medications were discontinued, and hydrocortisone was started.

43 iated pneumonia was unlikely and to consider discontinuing antibiotics.

44 Discontinued antiretroviral therapy (ART) results in unc

45 ded QT prolongation, the need to prematurely discontinue any of the medications due to QT prolongatio

46 tients receiving apheresis at enrollment, 16 discontinued apheresis.

47 ed after delivery to continue ART (CTART) or discontinue ART (DCART).

48 There were 45 409 patients who discontinued ART, and 44% failed to reinitiate.

49 NCI SR patients who discontinued ASNase were not at elevated risk (HR, 1.2;

50 The safety of discontinuing aspirin in favor of P2Y(12) inhibitor mono

51 needed, including careful reconsideration of discontinuing asymptomatic left ventricular dysfunction

52 All antiarrhythmic drugs were discontinued at least 5 half-lives before the initiation

53 plain why clinical effect is lost if SLIT is discontinued at this point.

54 f 717 vs 126 [18%] of 716); few participants discontinued because of adverse events (16 [2%] in the t

55 No participants discontinued because of adverse events in the bictegravi

56 respectively), and no patients on veverimer discontinued because of an adverse event.

57 s received IL-2-DT on ART, but treatment was discontinued because of high toxicity and lymphopenia.

58 tinued therapy because of anaemia, and three discontinued because of moderate neutropenia.

59 or for which a second-line regimen had been discontinued because of side effects.

60 astic leukemia (ALL) treatment, but is often discontinued because of toxicity.

61 Treatment was discontinued because TA-TMA resolved at a median of 66 d

62 n >500 milliseconds and died 20 months after discontinuing bedaquiline of a cause not attributable to

63 In both groups drainage was discontinued before complete evacuation of pleural fluid

64 It remains uncertain whether BMAs should be discontinued before dentoalveolar surgery.

65 ued after discharge, and MOUDs should not be discontinued before discharge.

66 Dofetilide was discontinued before hospital discharge in 46 (27%) becau

67 notherapy if carboplatin and paclitaxel were discontinued before progression, in patients with HER2-n

68 18 patients discontinued before study completion, either to receive

69 o group were lost to follow-up and therefore discontinued before study end.

70 49%) were using asthma medication regularly (discontinued before testing in 25 [68%] children).

71 group and three (2%) in the lopinavir group discontinued before week 48.

72 in hospitals where contact precautions were discontinued but not in hospitals that maintained contac

73 Study enrollment was discontinued by the Scientific Monitoring Committee due

74 If patients discontinued carboplatin and paclitaxel before progressi

75 e later cohort appeared to be more likely to discontinue care early, and this outcome appeared to be

76 combination, and 30% of patients in this arm discontinued cetuximab due to toxicity.

77 elated infections, and six have been able to discontinue CGD-related antibiotic prophylaxis.

78 , 56 years; 60 [43%] women) who completed or discontinued chemotherapy and vitamin D3 (median follow-

79 early: OR = 0.58, 95% CI: 0.39, 0.85) versus discontinued communication.

80 Ontario, Canada, since 2012, some hospitals discontinued contact precautions for vancomycin-resistan

81 More women in the control group discontinued contraception for 1 to 2 weeks (N = 19, 13%

82 pants randomized to continue CPT (n = 86) or discontinue CPT (placebo, n = 86) as daily treatment for

83 CTN44723643) evaluated the noninferiority of discontinuing CPT in stabilized patients on antiretrovir

84 The myopia reversed when FD was discontinued, despite ONS, but eyes did not recover back

85 e longer than whites, and are less likely to discontinue dialysis.

86 to have been enrolled in hospice and to have discontinued dialysis before death.

87 transfer inhibitor (INSTI) class; 1 patient discontinued DTG/ABC/3TC due to an adverse event.

88 reported adverse events, and 5% of patients discontinued due mostly to musculoskeletal and flu-like

89 Three (9%) patients discontinued due to adverse events and four (12%) patien

90 Maribavir was discontinued due to adverse events in 41/120 (34%) patie

91 TAC/MMF groups, respectively (P = .024), and discontinued due to adverse events/infections in 25.0% a

92 85 patients, 50% completed the study and 11% discontinued due to AEs.

93 se events were reported, and no participants discontinued due to an adverse event.

94 ad hydroxychloroquine+/-azithromycin held or discontinued due to an average QT prolongation of 60.5+/

95 o reduce inflammation following SCI, yet was discontinued due to an unfavorable risk-benefit ratio as

96 /C/F/TAF was well tolerated, no participants discontinued due to baseline resistance stopping criteri

97 e events in 41/120 (34%) patients, and 17/41 discontinued due to CMV infections.

98 -suppressed animals, the treatment had to be discontinued due to high toxicity and lymphopenia.

99 Ibrutinib was discontinued due to progressive disease in 27% of patien

100 study drug related, and 1 (<1%) participant discontinued due to study drug related AE(s).

101 study drug-related, and 1 (<1%) participant discontinued due to study drug-related AE.

102 fumarate, emtricitabine, and efavirenz group discontinued due to treatment-related adverse events, of

103 endpoint was the proportion of participants discontinuing due to adverse events (AEs) through Week 4

104 Patients who completed cycle 1 or discontinued during cycle 1 due to an adverse event or d

105 45 group and four (17%) in the placebo group discontinued during the treatment period.

106 is, were more frequent with APR40, which was discontinued during the trial.

107 A total of 359 trials (8.5%) were discontinued early, and 530 trials (12.6%) had unknown s

108 n disease-free in the months and years after discontinuing effective, but pricey, targeted therapies.

109 11.0 months (IQR 6.8-23.0), all patients had discontinued enasidenib, with a median of 3 treatment cy

110 Signatures of discontinued exposures, including tobacco smoke and ultr

111 than baseline levels among participants who discontinued FA supplementation.

112 who required enteric nutrition were able to discontinue feeding tube use; and 1 of 9 patients who re

113 Antihypertension medication was discontinued for a 2-week period before randomization.

114 Patients discontinued for disease progression (n = 25), adverse e

115 One subject discontinued for nonserious adverse events.

116 ponding patients continuing on EPAG had drug discontinued for robust response; 5 of the 15 required E

117 TACE was discontinued for toxicity in four of 44 (9%) participant

118 No children died or were discontinued from rivaroxaban because of adverse events.

119 luated patients who were not treated, 5 were discontinued from the drug treatment program or did not

120 Fifty-one patients (11.9%) discontinued from the study during the double-blind phas

121 lusive and do not justify recommendations to discontinue guideline-directed antihypertensive treatmen

122 Trials were less likely to be discontinued if funded by sources other than industry (h

123 Thirty-eight (66%) patients discontinued IM after a median of 7 (range 1-80) months.

124 , autoantibody formation was associated with discontinued immunosuppression and food allergy, with od

125 remained transfusion dependent, and 14 (88%) discontinued immunosuppression.

126 Emapalumab was discontinued in 1 patient because of disseminated histop

127 Adalimumab was discontinued in 151 patients.

128 GCSF could be discontinued in 2 patients and tapered by 57% and 81%, r

129 assay for anti-HCV-reactive samples but was discontinued in 2013.

130 The randomized drug regimen was discontinued in 34.6% and 13% of patients in the EVR/rTA

131 ents, hydroxychloroquine+/-azithromycin were discontinued in 58 patients (86.6%), while one or more d

132 Therapy was discontinued in 6 patients (in 1 because of an adverse e

133 99 received pre-admission digoxin, which was discontinued in 721 patients.

134 , being AEs the main cause of reduction, and discontinued in 84% (60% symptomatic progression, 33% AE

135 Randomised therapy was discontinued in 973 (32.4%) patients in the febuxostat g

136 We predicted that if PCV use is discontinued in Kenya in 2022, overall IPD incidence wil

137 ve come from recent trials where aspirin was discontinued in specific clinical scenarios, including e

138 s of selinexor; however, the 100 mg dose was discontinued in the protocol (version 7.0) on March 29,

139 lly for HHV-6 infection, whereas therapy was discontinued in the remaining 2 patients.

140 agnosis of IC for 5 years, or until patients discontinued insurance coverage, or until patients' firs

141 in seven of the eight infants, of whom four discontinued intravenous immune globulin supplementation

142 ants completed the full study, and six (17%) discontinued it prematurely because of loss to follow-up

143 eported no episodes of pancreatitis until he discontinued ivacaftor.

144 one dose modification, and 18 of 32 patients discontinued lenvatinib for drug-related issues.

145 ks after subjects 2 and 3, respectively, had discontinued LET prophylaxis and received preemptive the

146 Adults who discontinued lumacaftor-ivacaftor, often owing to advers

147 rachomatous inflammation-follicular (TF) and discontinue mass drug administration (MDA) with oral azi

148 therapy (ART) soon after infection and then discontinued, may inform HIV cure interventions.

149 nresponsiveness (SU) challenge 8 weeks after discontinuing MOIT.

150 cluded patients on natalizumab and those who discontinued natalizumab but remained in TOP.

151 A total of 3210 patients (52.2%) discontinued natalizumab; 2117 (34.4%) withdrew from TOP

152 atients who initiated nintedanib permanently discontinued nintedanib because of diarrhoea.

153 R) or complete response (CR) within 6 months discontinued nivolumab and were observed (arm A).

154 e patients (14%) were allocated to arm A and discontinued nivolumab, of whom five (42%; 90% CI, 18% t

155 (27%) of 45 patients with > 90 day follow up discontinued NSBB, most commonly for hypotension and AKI

156 tients with persistent viral suppression who discontinued nucleotide analogue use after extended trea

157 or personal preference, whereas 81 patients discontinued OAC after LAAO device implantation without

158 Among those who discontinued OAC, the median time to discontinuation was

159 (250, 4000) mg peanut protein, whereas 24.5% discontinued OIT.

160 ma Control Questionnaire (ACQ)-5 score >=1.5 discontinued omalizumab and immediately commenced mepoli

161 e as in the standard group, but the drug was discontinued on day 40.

162 0 mg peanut protein through to week 104 then discontinued on peanut (peanut-0 group), to be built up

163 All immunosuppression was discontinued on postoperative day (POD) 28.

164 ials initiated for rare diseases were either discontinued or not published 4 years after completion,

165 zumab ARRs were similar between patients who discontinued or remained on natalizumab, suggesting limi

166 mary outcome was tolerance of PPI cessation (discontinued or resumed PPIs).

167 8 patients were enrolled in trials that were discontinued or unpublished 4 years after completion.

168 ble toxicity, the investigator's decision to discontinue, or participant withdrawal.

169 ment strategy for deciding when to continue, discontinue, or reinstitute antifungal treatments.

170 n former users immediately (<=2 years) after discontinued oral contraceptive use (HR = 1.55; 95% CI,

171 s occurred in 66 patients (12%), and 30 (6%) discontinued owing to a treatment-related adverse event.

172 ts have been trialled, but several have been discontinued owing to safety concerns.

173 ite guideline recommendations, many patients discontinue P2Y12 inhibitor therapy earlier than the rec

174 Significant number of POPH patients discontinued PA-targeted therapy after LT.

175 ACTICE ADVICE 12: Clinicians should consider discontinuing pancreas cancer screening in high-risk ind

176 After the drug was discontinued, parasitism rebounded, and immunopathology

177 njugate vaccine (PCV) use at full cost or to discontinue PCV in their childhood immunisation programm

178 Four patients discontinued pembrolizumab because of immune-related adv

179 Eligible patients who discontinued pembrolizumab with stable disease or better

180 o receive darolutamide; 137 patients who had discontinued placebo before unblinding had occurred rece

181 In 50% of patients, VM can be discontinued post-LT (95% CI, 38-62).

182 AET > 4.0% had a 10 times increased odds of discontinuing PPI than participants with 4 days of AET >

183 n reflux monitoring predicted the ability to discontinue PPIs without symptom escalation.

184 reflux monitoring to predict the ability to discontinue PPIs.

185 Thirty-four participants (34%) discontinued PPIs.

186 Guidelines suggest to discontinue PrEP when a person is no longer at risk for

187 Safely discontinuing PrEP also requires greater understanding o

188 Frequently reported reasons for discontinuing PrEP were low perceived risk of HIV (25%),

189 ust continue to attend health-care visits or discontinue prophylaxis in consultation with a health-ca

190 best practice advisory resulted in providers discontinuing propofol an average of 16.6 hours (95% CI,

191 ement request, guidelines will be adapted or discontinued, rather than endorsed.

192 tinuation as monotherapy if the doublet were discontinued, resulted in significant and durable improv

193 of continuous ring use; eight were asked to discontinue ring use early because of ulcerations (grade

194 event that did not resolve within 7 days of discontinuing ruxolitinib would serve as a clinical indi

195 tancy of 10 years or less, clinicians should discontinue screening for breast cancer.

196 GUIDANCE STATEMENT 3: Clinicians should discontinue screening for colorectal cancer in average-r

197 Of all 531 patients treated, 12 (2%) discontinued selpercatinib owing to drug-related adverse

198 She discontinued several but not all of her NHPs after her i

199 None of the patients discontinued sofosbuvir-velpatasvir-voxilaprevir therapy

200 suggested that more than 90% of patients who discontinued statin treatment could be rechallenged with

201 tients allocated to apabetalone than placebo discontinued study drug (114 [9.4%] vs 69 [5.7%]) for re

202 patients in the respective treatment groups discontinued study drug because of an adverse event.

203 Overall, 46.7% of subjects discontinued study medication (KM rate by study end 50.9

204 Five (9%) patients discontinued study treatment because of treatment-relate

205 during study treatment or within 30 days of discontinuing study treatment, which were the result of

206 erythropoiesis-stimulating agents or who had discontinued such agents owing to an adverse event.

207 Clinicians should discontinue testosterone treatment in men with age-relat

208 ndustry-funded trials were less likely to be discontinued than trials funded by healthcare centers (o

209 There are other patients who develop PTC-T, discontinue the antibiotic, and later develop IIH.

210 r to be nonobese patients who develop PTC-T, discontinue the antibiotic, and never develop PTCS again

211 s terminated prematurely and the decision to discontinue the study was made by the sponsor.

212 her divided via randomization to continue or discontinue the treatment.

213 An independent safety monitoring committee discontinued the APR40 dosage.

214 The percentage of patients who discontinued the assigned regimen because of adverse eve

215 One quarter of the patients discontinued the asthma treatment, but their HRQoL was b

216 Two programs previously provided SEE but discontinued the effort due to lack of an evidence-based

217 oseltamivir (n=205) twice a day; 11 patients discontinued the study before receiving any study treatm

218 91 (6.8%) participants discontinued the study drug (29 in the ozanimod 1.0 mg g

219 and transient adverse event; one participant discontinued the study drug owing to a rash.

220 f 59) and B(200)PaZ (five [8%] of 60) groups discontinued the study drug than in the HRZE group (two

221 imegepant and four (1%) who received placebo discontinued the study due to an adverse event; no patie

222 No subjects randomized to BBFC discontinued the study.

223 We discontinued the trial at a median follow-up of 1.1 year

224 Three children (6% of participants) discontinued the trial during the first 10 minutes of th

225 ercentage of patients in the maribavir group discontinued the trial medication because of an adverse

226 high-dose group, and 1 in the placebo group discontinued the trial regimen because of adverse events

227 The number of patients who discontinued the trial regimen was higher in the standar

228 attributed to rejection, but improved after discontinuing the checkpoint inhibitor.

229 Unfortunately, when treatments are discontinued, the disease state often returns as patient

230 guing against the need for women with IIH to discontinue their use.

231 Twenty-nine patients (26.4%) had discontinued their medication, and six (5.5%) used ICS p

232 atin therapy (3.6% versus 2.0%; P<0.001), or discontinued their statin (10.9% versus 6.1%; P<0.001).

233 us 73.2%; P<0.001) and more likely to report discontinuing their statin because of a side effect (7.9

234 ing treatment; however, a substantial number discontinue therapy because of toxicities.

235 levels of less than 15 kU/L were allowed to discontinue therapy early.

236 prolongation, clinicians seldomly needed to discontinue therapy.

237 ular responses, up to half have been able to discontinue therapy.

238 1.30, 95% CI 1.02-1.65) were more likely to discontinue therapy.

239 No patient discontinued therapy because of anaemia, and three disco

240 Overall, 18 (22%) of 83 patients discontinued therapy due to treatment-related toxicity.

241 One participant discontinued therapy owing to a rash.

242 chieved HIV-1 RNA <50 copies/mL and very few discontinued therapy.

243 chieved HIV-1 RNA <50 copies/mL and very few discontinued therapy.

244 ata cutoff (September of 2019), all patients discontinued therapy; 33 received the planned 6 cycles.

245 se, as white spots often recur rapidly after discontinuing therapy.

246 Discontinuing these medications in COVID-19 patients may

247 ory deficits severe enough for many women to discontinue this life-saving treatment.

248 rrently prescribe eplerenone for CSCR should discontinue this practice.

249 emotherapy-induced neuropathy is to limit or discontinue this treatment.

250 t, at the end of the CSD period, PLX5622 was discontinued to allow microglial repopulation.

251 ng promising outcomes: patients were able to discontinue transfusions or had reduced transfusion requ

252 out of four evaluable pediatric participants discontinued transfusions after gene therapy and were tr

253 death in opioid use disorder, most patients discontinue treatment within a few weeks or months.

254 memory impairments, causing many patients to discontinue treatment.

255 se in bone marrow after 2 years were able to discontinue treatment.

256 After exclusion of patients who discontinued treatment (n=1 in the PENFS group; n=7 in t

257 o did not achieve SVR12 was a 4-year-old who discontinued treatment after 3 days because of "abnormal

258 ho did not achieve SVR12 was 3 years old and discontinued treatment after 5 days because of an advers

259 orial Sloan Kettering from 2009-2018 who had discontinued treatment and had at least 3 months of foll

260 (120 [74%] of 163 vs 105 [65%] of 161), and discontinued treatment as a result (24 [15%] vs eight [5

261 75%) had stable disease, two patients (6.3%) discontinued treatment as a result of toxicity before th

262 In our cohort, most patients discontinued treatment at the time of CR.

263 Few ozanimod-treated participants discontinued treatment because of adverse events (13 [2.

264 both trials, the proportion of patients who discontinued treatment because of adverse events was low

265 occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events.

266 Three (5%) of 60 children discontinued treatment because of elevated serum aminotr

267 One patient discontinued treatment because of grade 2 extremity pain

268 Eight patients discontinued treatment because of side effects.

269 Five patients discontinued treatment because of toxic effects possibly

270 Four patients (3%) discontinued treatment because of treatment-related adve

271 Six (7%) of 92 patients discontinued treatment because of treatment-related adve

272 Only four patients discontinued treatment before week 4 due to non-hepatic

273 atients with laBCC with CR on vismodegib who discontinued treatment between March 2012 and January 20

274 4%) of 426 patients in the secukinumab group discontinued treatment by week 52 versus 101 (24%) of 42

275 ated adverse events (mostly grade 1-2); none discontinued treatment due to adverse events.

276 7 patients; the 61 patients without MRD data discontinued treatment during induction and were conside

277 patients did not complete the study, and 11 discontinued treatment early.

278 Patients who discontinued treatment had significant decrease in ppFEV

279 (25%) of 92 relapsed or refractory patients discontinued treatment on study.

280 Nine patients discontinued treatment or were lost to follow-up before

281 ed with placebo, fewer patients on veverimer discontinued treatment prematurely (3% vs 10%, respectiv

282 Although nearly a third of patients discontinued treatment primarily because of oropharyngea

283 The mean VA of eyes from both regions that discontinued treatment within 10 years had fallen below

284 d lumacaftor-ivacaftor, 18.2% (154 patients) discontinued treatment, often owing to respiratory (48.1

285 completed the full treatment course and one discontinued treatment.

286 e (7%) patients died more than 30 days after discontinuing treatment because of progressive disease (

287 therapy less frequently, while declining and discontinuing treatment more frequently, accounted for t

288 atients but was not severe enough to warrant discontinuing treatment.

289 patients on pamrevlumab and seven on placebo discontinuing treatment.

290 oup and two (4%) patients in the HF-HD group discontinued trial treatment.

291 patients with chronic myeloid leukaemia have discontinued tyrosine kinase inhibitor (TKI) treatment a

292 adding 66 new resources and eliminating 147 discontinued URLs, bringing the current total to 1613 da

293 adding 65 new resources and eliminating 125 discontinued URLs; so bringing the current total to 1637

294 first line of therapy consists of advice to discontinue use of alcohol and smoking and taking analge

295 This study investigated continued and discontinued use of angiotensin-converting enzyme inhibi

296 facturer (>=3 tests per week); 24.7% of eyes discontinued use within 1 year.

297 ional US$15.8 million annually compared with discontinuing vaccination.

298 tion in symptom burden was greater among the discontinued versus resumed PPI group (RESQ-eD, -43.7% v

299 StudyPopulation: Three patients who have discontinued wearing of the ocularist-made exenteration

300 iving at least 24 months of pembrolizumab or discontinued with complete response after at least 6 mon